OPRX OptimizeRx
OptimizeRx earnings company data as of 4:46 AM ET 10/25
Scheduled
1 period, newest first, nothing reported yet. Each row shows EPS above revenue.
| Period | Date | Metric | Estimate | Actual | Result |
|---|---|---|---|---|---|
| FY2026 Q3 | 5 Nov | EPS | 0.08 | — | — |
| Rev | — | — | — |
Insider trades
Open-market buys and sales by OPRX's executives, directors and 10% owners in the last 12 months, from their Form 4s
- None no insider bought on the open market
- $19K sold by 1 insider outside a trading plan
- None no planned (10b5-1) sales
-
Edward Stelmakh Chief Finance & Strat OfficerSale$19K 1,388 shares at $13.51 1.1% of stakeTraded Dec 19, 2025 Filed Dec 22, 2025
Also filed in the last 12 months, not counted as buying or selling: 25 share withholdings for taxes, 11 stock grants, and 5 option exercises.
SEC filings
Recent issuer filings from EDGAR, 17 shown.
| Filed | Form | Detail | Links |
|---|---|---|---|
| SCHEDULE 13G/A | — | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| 10-Q | Filing Doc | ||
| 8-K | 2.02,5.02,7.01,9.01 | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| 8-K | 5.02,5.07,9.01 | Filing Doc | |
| 8-K | 5.02 | Filing Doc | |
| DEFA14A | DEFINITIVE ADDITIONAL MATERIALS | Filing Doc | |
| 10-Q | Filing Doc | ||
| 8-K | 1.01,1.02,2.02,2.03,9.01 | Filing Doc | |
| DEF 14A | PROXY STATEMENT | Filing Doc | |
| 8-K | 5.02,7.01,9.01 | Filing Doc | |
| 8-K | 4.01,9.01 | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 10-K | Filing Doc | ||
| 8-K | 1.01,2.02,8.01,9.01 | Filing Doc |
No filings match this filter.
Estimates are consensus figures; SEC filings remain the official record. Not investment advice.